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Commentary to the article  
“Metabolic syndrome is associated with  
different clinical outcome after cardiac  
resynchronization therapy in patients with  
ischemic and non-ischemic cardiomyopathy”
I have read the article entitled “Metabolic syn-
drome is associated with different clinical outcome 
after cardiac resynchronization therapy in patients 
with ischemic and non-ischemic cardiomyopathy” 
by Szepietowska et al. [1], recently published in 
“Cardiology Journal”, with great interest. The 
investigators reported that obese non-ischemic 
cardiomyopathy patients derive significant benefit 
from cardiac resynchronization with defibrillator 
therapy (CRT-D) if they present with metabolic 
syndrome (MS), whereas obese patients without 
MS show no significant reduction in events. On the 
contrary, obese ischemic cardiomyopathy patients 
with MS show no benefit from cardiac resynchro-
nization therapy (CRT), while obese ischemic 
patients without MS show significant reduction in 
the risk of events [1]. Szepie towska et al. [1] have 
claimed that intrinsic properties of myocardium 
fuel metabolism affected by MS may play a role in 
response to CRT.
Because of continuous contractile activity, the 
heart has a very high energy demand. About 95% 
of this energy is normally obtained by production of 
adenosine triphosphate (ATP) from mitochondrial 
oxidative metabolism, while the remaining 5% 
originates from glycolytic ATP production. The 
source of fuel for mitochondrial oxidative metabo-
lism normally comes from a balance between fatty 
acids and carbohydrates, and to a lesser degree 
ketones and amino acids [2].
In the event of heart failure, there is a switch 
from mitochondrial oxidative metabolism to an 
increase in glucose uptake and glycolysis [3]. This 
increase in glucose uptake and glycolysis can occur 
even though mitochondrial glucose oxidation is 
impaired, resulting in an uncoupling of glycolysis 
from glucose oxidation. This uncoupling produces 
lactate and [H+], which decreases the efficiency of 
the heart [3]. The heart has a strict reciprocal rela-
tionship between fatty acid oxidation and glucose 
oxidation, so that a increase in fatty acid oxidation 
is associated with decrease in glucose oxidation 
and vice versa [2].
Trimetazidine is a fractional fatty acid oxida-
tion inhibitor that inhibits 3-ketoacyl CoA thiolase, 
one of the enzymes of fatty acid beta-oxidation. 
This results in an increase in glucose oxidation. Tri-
metazidine improves endothelial function, reduces 
calcium overload and free radical-induced injury, as 
well as inhibits cell apoptosis and cardiac fibrosis 
via increased high-energy phosphate levels [4].
Brottier et al. [5] demonstrated that trimetazi-
dine therapy was related to improvement in left 
ventricular function. El-Kady et al. [6] reported 
that trimetazidine could reduce the risk of cardio-
vascular events in heart failure patients.
In the light of this knowledge, trimetazidine 
therapy could influence response to CRT treat-
ment in patients with heart failure. Authors should 
elucidate the relationship between trimetazidine 
treatment and response to CRT treatment.
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